Abstract：
UNASSIGNED: Evaluate potential effects of calcium channel blockers (CCB) and bisphosphonates (BP) on residual hearing following cochlear implantation.
UNASSIGNED: Medications of 303 adult hearing preservation (HP) candidates (low frequency pure tone average [LFPTA] of 125, 250, and 500 Hz ≤80 dB HL) were reviewed. Postimplantation LFPTA of patients taking CCBs and BPs were compared to controls matched by age and preimplantation LFPTA.
UNASSIGNED: Twenty-six HP candidates were taking a CCB (N = 14) or bisphosphonate (N = 12) at implantation. Median follow-up was 1.37 years (range 0.22-4.64y). Among subjects with initial HP, 29% (N = 2 of 7) CCB users compared to 50% (N = 2 of 4) controls subsequently lost residual hearing 3-6 months later (OR = 0.40, 95% CI = 0.04-4.32, p = 0.58). None of the four BP patients with initial HP experienced delayed loss compared to 50% (N = 2 of 4) controls with initial HP (OR = 0.00, 95% CI = 0.00-1.95, P = 0.43). Two CCB and one BP patients improved to a LFPTA <80 dB HL following initial unaided thresholds that suggested loss of residual hearing.
UNASSIGNED: There were no significant differences in the odds of delayed loss of residual hearing with CCBs or BPs.
UNASSIGNED: Further investigation into potential otoprotective adjuvants for maintaining residual hearing following initial successful hearing preservation is warranted, with larger cohorts and additional CCB/BP agents.
UNASSIGNED: Medications of 303 adult hearing preservation (HP) candidates (low frequency pure tone average [LFPTA] of 125, 250, and 500 Hz ≤80 dB HL) were reviewed. Postimplantation LFPTA of patients taking CCBs and BPs were compared to controls matched by age and preimplantation LFPTA.
UNASSIGNED: Twenty-six HP candidates were taking a CCB (N = 14) or bisphosphonate (N = 12) at implantation. Median follow-up was 1.37 years (range 0.22-4.64y). Among subjects with initial HP, 29% (N = 2 of 7) CCB users compared to 50% (N = 2 of 4) controls subsequently lost residual hearing 3-6 months later (OR = 0.40, 95% CI = 0.04-4.32, p = 0.58). None of the four BP patients with initial HP experienced delayed loss compared to 50% (N = 2 of 4) controls with initial HP (OR = 0.00, 95% CI = 0.00-1.95, P = 0.43). Two CCB and one BP patients improved to a LFPTA <80 dB HL following initial unaided thresholds that suggested loss of residual hearing.
UNASSIGNED: There were no significant differences in the odds of delayed loss of residual hearing with CCBs or BPs.
UNASSIGNED: Further investigation into potential otoprotective adjuvants for maintaining residual hearing following initial successful hearing preservation is warranted, with larger cohorts and additional CCB/BP agents.
摘要：
■评估钙通道阻滞剂（CCB）和双膦酸盐（BP）对人工耳蜗植入后残余听力的潜在影响。
■对303名成人听力保留（HP）候选人（125、250和500Hz≤80dBHL的低频纯音平均值[LFPTA]）的药物进行了审查。将接受CCB和BP的患者的植入后LFPTA与年龄和植入前LFPTA相匹配的对照组进行比较。
■26名HP候选人在植入时服用CCB（N=14）或双膦酸盐（N=12）。中位随访时间为1.37年（范围0.22-4.64年）。在初始HP的受试者中，29％（7个中的N=2）CCB用户与50％（4个中的N=2）对照在3-6个月后失去残余听力（OR=0.40，95％CI=0.04-4.32，p=0.58）。与50％（4个中的N=2）的初始HP对照组相比，四名初始HP的BP患者均未出现延迟减轻（OR=0.00，95％CI=0.00-1.95，P=0.43）。两名CCB和一名BP患者在最初的独立阈值表明残余听力损失后改善至LFPTA<80dBHL。
■与CCB或BP相比，残余听力延迟丧失的几率没有显着差异。
■有必要对潜在的耳保护佐剂进行进一步研究，以维持最初成功的听力保留后的残余听力。更大的队列和额外的CCB/BP药物。
■对303名成人听力保留（HP）候选人（125、250和500Hz≤80dBHL的低频纯音平均值[LFPTA]）的药物进行了审查。将接受CCB和BP的患者的植入后LFPTA与年龄和植入前LFPTA相匹配的对照组进行比较。
■26名HP候选人在植入时服用CCB（N=14）或双膦酸盐（N=12）。中位随访时间为1.37年（范围0.22-4.64年）。在初始HP的受试者中，29％（7个中的N=2）CCB用户与50％（4个中的N=2）对照在3-6个月后失去残余听力（OR=0.40，95％CI=0.04-4.32，p=0.58）。与50％（4个中的N=2）的初始HP对照组相比，四名初始HP的BP患者均未出现延迟减轻（OR=0.00，95％CI=0.00-1.95，P=0.43）。两名CCB和一名BP患者在最初的独立阈值表明残余听力损失后改善至LFPTA<80dBHL。
■与CCB或BP相比，残余听力延迟丧失的几率没有显着差异。
■有必要对潜在的耳保护佐剂进行进一步研究，以维持最初成功的听力保留后的残余听力。更大的队列和额外的CCB/BP药物。
